TFR

Trading Floor Research

Welcome to the Trading Floor

08/09/26

This Trading Floor Research report contains:

Basic Materials Update

Inhibikase Therapeutics (IKT)

Basic Materials Update

On Wednesday, a day after issuing a new buy signal, the **basic materials sector** surged 2.31% on above-average volume, driving overall accumulation sharply higher. This is exactly the confirmation needed for a higher probability of a sustained uptrend.

The sector's advance was fueled by strong group moves in **gold, silver, industrial metals,** and **copper miners**, all of which generated their first buy signals since topping in late February.

Gold miners led the way with a massive 7.28% gain on volume that was 48.5% above average. **Gold (GLD)** reinforced the move with a confirmed buy signal on heavy volume after finding support at its 1.618 Fibonacci expansion.

On Friday, the **basic materials sector** once again led the market higher with a 2.4% advance on above-average volume, up 25.1%. With miners now in a buy signal—supported by the metal and massive accumulation—my focus is on mining leaders that should provide further confirmation in the next few sessions.

Basic Materials

Gold miners Industry Group

Gold (GLD)

436.51
418.21
418.21
399.88
398.47
368.78
50.0 (436.51)
37.5 (418.21)
25.0 (399.92)
12.5 (381.62)
May 2026
Jun 2026
Jul 2026
8/7/2026
Buy
Sell
Arith
Volume
Moving Average 50
13.3M
Up/Down Volume Ratio
Donchian Channels 20
Donchian Channels 20
Donchian Channels 45
Three sessions of heavy volume as accumulation climbs
1.31

Confirmed Buy: Inhibikase Therapeutics (IKT)

- ***Industry Group: Biotechnology.*** *The healthcare sector's massive accumulation stood out significantly above most other sectors this past week. With accumulation surging in healthcare stocks, the sector's advance should continue to set it apart from the rest of the field, and it remains my primary focus for identifying emerging leaders. To capitalize on this strength, I purchased* ***Inhibikase Therapeutics (IKT)*** *after receiving my confirmation signal at 2.37.*
- **Inhibikase Therapeutics (IKT)** is a clinical-stage pharmaceutical company developing protein kinase inhibitors for cardiopulmonary and neurodegenerative diseases, with a primary focus on treating Pulmonary Arterial Hypertension (PAH).
- *Overall accumulation is soaring as* ***Inhibikase Therapeutics (IKT)*** *breaks out of its eight-month base, signaling renewed investor interest and strong underlying demand. Notably, the stock has just achieved its first close above the weekly cloud in over a year. Finishing the week above the weekly cloud is a significant technical milestone, as it often marks the transition from a consolidation phase to the start of a sustained advance. This setup suggests IKT could be poised for a meaningful move higher.*
- The **Inhibikase Therapeutics (IKT)** position was started at 1/2-star.
- Inhibikase Therapeutics (IKT) ***was purchased at 2.37.***
- Inhibikase Therapeutics (IKT) *is undergoing significant accumulation, reaching 95-day highs.*
- **Inhibikase Therapeutics (IKT) closed at 2.97.**
- Inhibikase Therapeutics (IKT) ***has an anchored VWAP of 26.55.***
- ***The Fibonacci sell targets****: 1st target 2.63; 2nd target 2.77; 3rd target is 3.10; 4th target is 3.48; 5th target is 4.20.*
- *Stop price: Close below 2.23.*

Inhibikase Therapeutics (IKT)

Inhibikase Therapeutics (IKT) Weekly Chart



Disclaimer

Before using this site, please make sure that you note the following important information:

Do your Own Research

Our content is intended to be used and must be used for informational purposes only. It is very important to do your own analysis before making any investment based on your own personal circumstances. You should take independent financial advice from a professional in connection with, or independently research and verify, any information that you find on our Website and wish to rely upon, whether for the purpose of making an investment decision or otherwise.

The content of this email is confidential and intended only for the recipient specified in the message. It is strictly forbidden to share any part of this message with any third party without the written consent of the sender. If you received this message by mistake, please reply to this message and follow with its deletion so that we can ensure such a mistake does not occur in the future.

TFR

Trading Floor Research

Welcome to the Trading Floor

The results do not represent the performance of all selections made by the Trading Floor Research (TFR) newsletter.

We look for investment resources and inform you of these resources, which you may choose to use in making your own investment decisions. **Past performance is no guarantee of future results. Inherent in any investment is the potential for loss.** This material is being provided for informational purposes only, and nothing herein constitutes investment, legal, accounting, or tax advice or a recommendation to buy, sell, or hold a security. No recommendation or advice is given on whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors, or markets identified and described were or will be profitable. All information is current as of the date herein and is subject to change without notice.